Eucure Biopharma is a China based innovative biotechnology company with global vision, specializing in developing innovative antibody drugs with independent intellectual property rights. Eucure Biopharma owns a seasoned team with in-depth experience in global clinical development, and is dedicated to providing a comprehensive range of professional services, including clinical medicine, science, clinical operations, regulatory registrations, data management, biostatistics, clinical supply chain, CMC, pharmacology & toxicology, clinical safety and pharmacovigilance. Eucure Biopharma has set up offices in Beijing, Shanghai and the United States according to the company's development strategy. And these branches are responsible for conducting global clinical trials mainly in China, the United States and Australia. Eucure Biopharma owns a clinical development team experienced in comprehensive global and domestic drug development, and has a good relationship network at the operational level of clinical trials in China, the United States and Australia. In addition, our team has the ability to integrate clinical development functions. Eucure Biopharma has the core competitiveness in project strategy, registration affairs (U.S. Food and Drug Administration, and China National Medical Products Administration), clinical study protocol design, efficient and massive clinical operation implementation, and cooperation with KOL/PI. In addition, Eucure Biopharma has built a comprehensive development governance system covering development supervision, standardized operating procedures (SOPs), and systematic supplier assessment and management processes, all of which are designed to ensure patients' safety. Eucure Biopharma is a wholly-owned subsidiary of Biocytogen committed to clinical development. Since its establishment in October 2019, Eucure Biopharma's clinical development team has built robust development pipelines for over ten targets self-developed by Biocytogen. Currently, three R&D products have obtained investigational new drug application (IND) approvals from China NPMA, and two of them have obtained (IND) approvals from U.S. FDA. All three R&D products have entered Phase I clinical trials in Australia, including one entered Phase II in Australia . One of them has entered Phase I clinical trials in China, two R&D products are about to enter Phase I clinical trials in China. All these achievements serve as the best proof of Eucure Biopharma's strength in clinical development.